

Blackpeak Healthtech market update

February 2026



Scott Colvin, Managing Director

Scott@blackpeakcapital.com.au

Executive summary

- Blackpeak are pleased to present our industry vertical report on the ANZ Healthtech market – we think about the Healthtech software market in terms of two broad categories:
- **Clinical & Patient Care solutions** – software that is utilised across a patient journey, from prevention & telehealth to diagnostic and monitoring
- **Workflow & practice management solutions** – software used by administrators to streamline administrative & operational tasks within a hospital or healthcare clinic including bookings, Practice Management and EHR software
- The ANZ Healthtech software market is undergoing a period of rapid growth, with increasing levels of investment & M&A activity driven by structural shift towards fully digital connected health systems which is underpinned by:
 - Increasing adoption of AI solutions across the patient journey e.g. Clinical Support, Diagnostics & imaging as well as workflow & practice management solutions that streamline critical functions including scheduling sharing of patient records, invoicing & payments;
 - Focus on interoperability as health care systems practitioners move away from often multiple fragmented and legacy systems into modern, unified systems;
 - Increasing focus on virtual & remote care with telehealth & remote patient monitoring now embedded in standard healthcare service offerings; and
 - Shift to preventative care through enhanced data sharing, analytics & risk identification
- Australia & New Zealand has produced an impressive list of companies within the Healthtech market ecosystem that are set to capitalise on the increasing adoption of technology

Contents

1	Page: 4	Blackpeak credentials
2	Page: 5-11	ANZ Healthtech landscape
3	Page: 12-19	Healthtech M&A & private fundraising trend
4	Page: 20-26	Acquisition and private raising detail
5	Page: 27-35	Public raisings
6	Page: 36-38	Comparable trading detail

Blackpeak provides a suite of services across the company lifecycle

PRIVATE CAPITAL

Assisting companies and founders find the right partner for growth and/or sell-down

PRE-IPO CAPITAL

Experienced in advising companies with the final round of private fundraising before an IPO by considering investor suitability and structuring alternatives

IPO CAPITAL

Extensive experience in management and execution of IPO's with significant shareholder value realized by our clients

PUBLIC CAPITAL

Dedicated team of listed capital markets specialists to structure and execute on capital raisings for ASX-listed companies



PRIVATE M&A ADVISORY

With a focus on sell-side M&A, Blackpeak has a track record of achieving outstanding outcomes for our clients

PUBLIC MARKETS M&A

Extensive public markets M&A experience and capability sets Blackpeak apart from boutique competitors

DEFENCE ADVISORY

Extensive experience in the preparation, assessment and implementation of response strategies

STRATEGIC ADVISORY

Record of assisting clients achieve strategic growth ambitions and providing value for shareholders



ANZ Healthtech landscape

Clinical patient care & workflow solutions




ANZ healthcare is a large market broadly split between clinical and patient care vs administrative / workflow solutions


Clinical and Patient Care Solutions




Administrative / workflow software



Software adoption is driving improved outcomes through the patient journey



Software adoption is driving improved outcomes through the patient journey




Workflow




Improves the efficiency of healthcare institutions improving outcomes for patients and providers

However, software providers are increasingly consolidating across multiple verticals to deliver a seamless, all-in-one customer experience

ANZ healthcare ecosystem – Administrative & Workflow solutions



Domestic practice & care management software provide a variety of administrative and workflow solutions

 Hospitals	 GP & medical specialists	 Allied health & Dental	 Aged Care/ Disability
<p><i>Large public hospitals & healthcare providers</i></p> 	<p><i>General Practitioners & medical specialists</i></p> 	<p><i>Allied Health & Dental clinics</i></p> 	<p><i>Aged & Disability care management</i></p> 

Profiles available on all companies in market map – contact Blackpeak Capital for details.
Scott Colvin: scott@blackpeakcapital.com.au
Mark Leddy: mark@blackpeakcapital.com.au

Practice & care management platforms incorporate several workflow solutions tailored to suit the complex requirements specific to enterprises, private and allied health clinics

Administration and workflow solutions driving efficiencies across healthcare institutions

	Benefit	Vertical	Pain point	Solution	Example solutions
1	Connecting patients to practitioners	 Bookings, Marketplaces & referrals	<ul style="list-style-type: none"> Inefficiencies and fragmentation of the healthcare system results in underutilised capacity for clinics and long wait times for patients Time consuming & manual process to referral patients to specialists 	<ul style="list-style-type: none"> Bridge between patient demand and clinical supply improving access, efficiency and utilisation through digitised scheduling of appointments and referrals as well as increasing patient engagement 	
		 Communication / patient engagement	<ul style="list-style-type: none"> Fragmentation and complexity in healthcare ecosystem leads to communication breakdowns between patient and healthcare providers 	<ul style="list-style-type: none"> Enable proactive, personalised and automated communication to improve patient experience, adherence and operational efficiency 	
2	Managing large databases	 Electronic health records	<ul style="list-style-type: none"> Fragmented and inaccessible patient information across different healthcare providers 	<ul style="list-style-type: none"> Provides a unified, real-time view of patient history by centralising and securely sharing patient information 	
		 Data & analytics	<ul style="list-style-type: none"> Fragmented data silos make it difficult to extract insights 	<ul style="list-style-type: none"> Data analytics platforms aggregate, standardise and analyse health data, delivering real-time insights via dashboards 	
3	Optimising complex manual tasks	 Compliance	<ul style="list-style-type: none"> Complex and fragmented regulation creating significant administrative burdens and risks of non-compliance 	<ul style="list-style-type: none"> Automates compliance workflows, incident reporting and government funding tracking 	
		 Revenue cycle management	<ul style="list-style-type: none"> Hospitals and large providers lose revenue due to leakage (unbilled services, denied claims) Complex billing and compliance requirements 	<ul style="list-style-type: none"> Automates end-to-end billing, claims and revenue optimisation improving revenue capture 	
		 Payments	<ul style="list-style-type: none"> Healthcare payments require integration between: patients, service providers and health insurance/Medicare 	<ul style="list-style-type: none"> Digital payments platforms streamline claims, rebates and transactions 	



Healthtech M&A & private fundraising trends



Trends in private capital raising activity


Overview

- Private capital fundraising activity in Healthtech has remained robust despite challenging broader market conditions, with increasing activity in later stage rounds with larger cheque sizes attracting strong interest from local & global investors
- Workflow solutions around Practice Management, online bookings & Health Records were some of the first areas within Healthcare to become digitised
- Disruption as a result of the covid-19 pandemic necessitated a wave of change within the Healthcare market as Healthcare practitioners dealt with operational, staffing and service disruptions which lead to the broad adoption of telehealth
- Today, the rise of AI-driven tools to streamline decision support, workflow automation and diagnostic augmentation is driving the next wave of investment into Healthcare with notable capital raisings from Heidi, Harrison.ai and Lyerbird
- Blackpeak expects this trend to continue, along with an increased focus on AI within workflow solutions as Healthcare software becomes further embedded and as practitioners and administrators look for further ways to automate manual, administrative processes

Select private raisings

Date	Target	Investor(s)	Raising Size (A\$m)
Feb-26	splose	SPECTRUM EQUITY ATHLETIC VENTURES	46.00
Oct-25	Heidi	Point72 BLACKBIRD Headline	98.40
Mar-25	Sonder	BLACKBIRD seek HOSTPLUS MA Growth Ventures	40.00
Mar-25	Heidi	Headline ANTHROPIC MENLO BLACKBIRD HESTA possible	26.50
Jan-25	Harrison.ai	aware super ECP Horizons Ventures BLACKBIRD	179.00
Sep-24	VALD	FTV CAPITAL	n.a.
Apr-23	eucalyptus	BLACKBIRD //23 Woolworths BOND	50.00
Sep-21	Prospection	Horizons Ventures Z Ellerston Capital MAIN SEQUENCE CSIRO	45.00

Private capital raise volume / value⁽¹⁾



ANZ HealthTech Venture Capital and Growth Equity activity

Investor	Overview	Completed deals (#)
	<ul style="list-style-type: none"> One of the largest VC investors in ANZ, having completed +130 investments since inception with a strong focus on Healthtech 10 current HealthTech investments with most recent investment in AI doctor assist Heidi's US\$65m funding round 	
	<ul style="list-style-type: none"> Publicly listed investment fund (ASX:BTI) focusing on public and private high-growth expansion stage technology companies with two current Healthtech investments (updoc and access telehealth) Sold stake of of prescription management platform InstantScripts to Wesfarmers in May-22 realisation \$52m cash at an IRR and MoM of ~62%⁽¹⁾ and ~5x⁽²⁾ respectively 	
	<ul style="list-style-type: none"> One of the largest VC & growth investors across ANZ with +110 current investments Significant exposure to HealthTech with 9 current investments Most recent HealthTech investment included leading the \$12.5m funding round for Kismet, a disability & healthcare services platform 	
	<ul style="list-style-type: none"> ANZ-based global VC & growth equity investor Indicated a strong interest in Healthtech, driven by potential of AI and D2C models to transform healthcare Current portfolio includes 5 Healthtech investments, most recently leading a 6.3m seed round for AI healthcare workflow provider NexusMD.ai (Jun-25)⁽³⁾ 	
	<ul style="list-style-type: none"> Early-stage Venture Capital and growth equity investor focusing on B2B software companies in Australia and New Zealand Strong focus on Healthtech with 4 current Healthtech investments, most recently leading Allied Health Practice Management software Splose's \$5m funding round (Feb-25) 	

(1) ASX announcement 'Bailador exits its investment in InstantScripts for \$52m cash – 25% valuation uplift increases NTA by \$10.3m' (Jun-23)
 (2) Bailador FY25 Results presentation
 (3) SquarePeg press release 'Investment Notes: NexusMD A\$6.3 million – Square Peg' (Jun-25)

Healthtech platform assets:

Overview

- Established in 2013 as the digital health and technology arm of Telstra Corporation, since grown to become one of the leading digital domestic healthcare software providers
- Significant presence across health, aged care, pharmacy and government sectors serving over 1,200 healthcare providers with workforce of over 1,500 employees
- Established UK presence by acquiring Dr Foster in 2015, subsequently rebranding the entity to Telstra Health UK in July 2021 to unify its global identity
- Mixed growth strategy with capability to develop software organically and through bolt on acquisitions:
 - Established medical records provider Kyra Clinical in-house in Apr-21
 - Since establishment has completed 7 acquisitions in healthcare technology assets
- Awarded \$33m contract from the Australian Digital Health Agency to upgrade the My Record System to enhance the system’s capacity to handle increasing demands for health information sharing
- Telstra is rumoured to be considering strategic options for Telstra Health

Healthcare technology assets

Asset	Date	Overview
 Kyra Clinical	Apr-21	<ul style="list-style-type: none"> ▪ Electronic hospital medical records solution program ▪ Developed in-house
 MedicalDirector	Aug-21	<ul style="list-style-type: none"> ▪ Provider of healthcare technology solutions to medical practitioners, medical practices and hospitals ▪ Acquired at an EV of ~A\$350m
 PowerHealth	Jul-24	<ul style="list-style-type: none"> ▪ Specialist in healthcare costing and revenue software ▪ Acquisition of remaining 30% following initial 70% investment (Nov-21)
 FRED	May-24	<ul style="list-style-type: none"> ▪ IT solutions provider for pharmacy ▪ Acquired remaining 50% (Previously held 50% from previous investment in 2013)
 emerging SYSTEMS	Dec-14	<ul style="list-style-type: none"> ▪ Served as the foundational clinical engine for what is now the Kyra Clinical platform ▪ Founder Russel Duncan joined Telstra Health and served as CTO until late 2022
 HealthObject Healthcare IT. Simplified.	Dec-14	<ul style="list-style-type: none"> ▪ Cloud-enabled system deployed in over 250 hospitals across Asia ▪ Established a 50+ person development centre in Chennai
 dr foster	Mar-15	<ul style="list-style-type: none"> ▪ Acquired at an EV of ~A\$50m ▪ Improve efficiency while providing a platform to diversify revenue away from traditional telecommunications

Healthtech platform assets: Magentus



Overview

- Magentus was established in May 2023, through the consolidation of Citadel Health, together with Genie Solutions and Wellbeing Software
- The merger established Magentus as a healthcare software platform operating across Australia and the UK, providing enterprise clinical systems, specialist practice management software, and pathology informatics solutions
- Citadel Health provided the foundational enterprise clinical systems capability, including pathology, radiology and oncology information systems
- Genie Solutions expanded the platform into specialist practice management software, serving private medical practices and outpatient clinics
- As part of the platform build strategy, Magentus strengthened its pathology software capabilities through the acquisition of Labflow Pty Ltd, a cloud-native laboratory information management system provider
- The acquisition expanded Magentus' presence across both large diagnostic networks and mid-market laboratories, while accelerating the platform's transition toward cloud-enabled clinical infrastructure

Healthcare technology assets

Asset	Country	Date	Overview
 citadel group	AU	May-23	<ul style="list-style-type: none"> Specialised healthcare Administration software in AUS & the UK across Pathology, Oncology & Maternity Citadel health division was merged to form Magentus
 wellbeing software	UK	May-23	<ul style="list-style-type: none"> Specialist practice management software designed to streamline clinical and administrative tasks Part of Magentus formation
 Genie Solutions	UK	May-23	<ul style="list-style-type: none"> Specialised in clinical information management systems, particularly for radiology, maternity, pathology, and oncology Part of Magentus formation
 Labflow™	AU	Dec-25	<ul style="list-style-type: none"> AI-powered technology company specialising in cloud-native, automated workflow management software for pathology labs



Healthtech platform assets:

Overview

- Wesfarmers Health division was formed in March 2022, with the acquisition of API, one of Australia’s leading health and beauty companies for ~\$1.03Bn
- Wesfarmer Health comprises of a Wholesale segment and a consumer segment, which includes Retail, MediAesthetics and Digital Health
- The Retail business centres around Priceline which operates 419 community pharmacies across Australia and 68 non-pharmacy Priceline stores, employing over 3,000 team members
- Digital Health grew through the acquisition of InstantScripts (EV ~\$135M) and SiSU Health, which extended Wesfarmers Health into telehealth, e-prescriptions and preventative health screening
- MediAesthetics expansion was anchored by acquisitions of SILK Laser Clinics (Ev ~\$180M) and Clear Skincare, providing exposure to higher-margin, consumer-paid clinical services

Healthcare assets

Asset	Date	Overview
	Mar-22	<ul style="list-style-type: none"> Leading health, beauty, pharma wholesale and retail operator Acquired at an EV of \$1.03Bn
	Mar-22	<ul style="list-style-type: none"> Leading pharmacy, health & beauty retail network with 480+ outlets Part of API acquisition
	Sept-22	<ul style="list-style-type: none"> Leading ANZ skin, acne, cosmetic injecting and laser hair removal clinics
	Nov-23	<ul style="list-style-type: none"> Specialises in medical-grade laser hair removal, cosmetic injections, skin treatments, and body sculpting
	Jul-21	<ul style="list-style-type: none"> Chemist chain providing pharmacy services and professional care 50+ stores nation-wide
	Mar-22	<ul style="list-style-type: none"> API’s exclusive club for independent pharmacies, offering a suit of flexible programs, tools & services
	Mar-22	<ul style="list-style-type: none"> Provides professional service and advice, counselling patients on specific medication needs 50+ stores nationally

Healthcare technology assets

	Jul-2023	<ul style="list-style-type: none"> Online medical clinic providing 24/7 telehealth consultations with Australian-registered doctors
	Aug-2024	<ul style="list-style-type: none"> Provides self-service health stations Majority stake acquired in 2022; full ownership completed in 2024 (EV undisclosed)

Healthtech platform assets: Lanas

Overview

- Recently established in November 2025, post TA Associates' ~\$450m acquisition of Irish based multinational EHR technology provider Clanwilliam Group
- Committed M&A facility of US\$115m supported by investment from TA Associates, Apollo-managed funds, Hayfin Capital Management and Arcmont Asset management
- Generates ~\$120m in annual revenue from solutions across five core verticals – pharmacy, primary and community care, specialists, care platforms, and medical communications
- Multinational healthtech provider with presence in the UK, Ireland, Australia and New Zealand
- Historically grown through highly acquisitive strategy having completed 20+ investments since inception with 30 years in healthcare technology

Healthcare technology assets

Asset	Country	Date	Overview
 A Clanwilliam Company		Apr-17	<ul style="list-style-type: none"> Market-leading New Zealand pharmacy software provider Represents Clanwilliam's first meaningful entry into the NZ market
		Sep-17	<ul style="list-style-type: none"> Australasia's leading secure health messaging and e-referrals network Connects 15,000+ medical organizations across AU and NZ
		Jan-17	<ul style="list-style-type: none"> Specialist practice management and billing software provider for anaesthetists Clanwilliam's foundation AU acquisition
		May-18	<ul style="list-style-type: none"> A medical information request platform for insurance Merged with HealthLink in 2019 to create a unified health data exchange entity
		May-18	<ul style="list-style-type: none"> Provides software that analyses patient data to identify those at high risk of chronic disease Diversifies portfolio with high-value predictive capability
		Nov-18	<ul style="list-style-type: none"> Translates complex clinical research and medical data into actionable knowledge for healthcare professionals Expands into global scientific consultancy
		Nov-19	<ul style="list-style-type: none"> Leading digital health news platform Direct contact to 20,000+ ANZ healthcare professionals

Trends in M&A activity


Overview

- The ANZ Healthtech market has historically been characterised as a highly specialised and fragmented market, with lots of niche, sub-scale providers and dominant players often being specialised in specific sub verticals e.g. GP bookings software
- Emergence of scaled businesses across the Healthtech ecosystem creating increasing interest in M&A
 - The fragmented market of vertical-specific software creates strong appetite from strategics and sponsors due to the ‘mission critical’ nature of services provided
- The majority of M&A activity in ANZ has been focussed on software addressing administrative workflow solutions e.g. Bookings and Practice Management software which reflects the size and maturity of the market relative to clinical & patient care solutions software
 - Strong interest from both local & international sponsors & strategic buyers

Select M&A transactions

Date	Target	Acquirer	Enterprise Value (A\$m)	LTM Rev	ARR	LTM EBITDA	NTM EBITDA
Feb-26	eucalyptus	hims & hers	1,600	6.4x	3.6x	n.a.	n.a.
Dec-25	HotDoc	potentia	250.0+	n.a.	n.a.	n.a.	n.a.
Jun-25	Health Metrics	AKKR	300.0+ ⁽¹⁾	n.a.	n.a.	n.a.	n.a.
May-25	MedAdvisor (ANZ Business)	CONSTELLATION SOFTWARE INC.	42.4	1.7x	n.a.	10.1x	n.a.
Dec-24	ORION HEALTH	HEALWELL AI	182.1	n.a.	n.a.	n.a.	8.3x
Dec-23	Volpara HEALTH	Lunit	285.5	8.1x	n.a.	n.m	n.m
Jun-23	InstantScripts	api Wesfarmers	133.0	n.a.	n.a.	n.a.	n.a.
Aug-21	MedicalDirector	T Health	340.0	n.a.	n.a.	n.a.	n.a.

M&A volume / value⁽¹⁾





Acquisition and private raising detail



ANZ acquisitions⁽¹⁾

Transaction Overview							
Target	Date	Acquiror	Target Segment	Enterprise Value (A\$m)	EV/LTM Revenue	EV/NTM Revenue	EV/LTM EBITDA
	Feb-26		Telehealth	1,600	6.4x	n.a.	n.a.
	Dec-25		GP booking platform	250.0+	n.a.	n.a.	n.a.
	Dec-25		Pathology software	n.a.	n.a.	n.a.	n.a.
	Sep-25		Aged and disability care software	n.a.	n.a.	n.a.	n.a.
	Aug-25		Virtual care provider	n.a.	n.a.	n.a.	n.a.
	Jul-25		Pharmacy software	n.a.	n.a.	n.a.	n.a.
	Jun-25		Aged and disability care software	300.0+	n.a.	n.a.	n.a.
	Jun-25		Aged and disability care software	n.a.	n.a.	n.a.	n.a.
	Jun-25		Stroke prediction software	n.a.	n.a.	n.a.	n.a.
	May-25		Virtual Pharmacist	42.4	1.7x	n.a.	10.1x
	Feb-25		Practice management software	n.a.	n.a.	n.a.	n.a.
	Dec-24		Healthcare software solutions	182.1	n.a.	n.a.	n.a.
	Aug-24		Workforce management software	7.3	n.a.	n.a.	n.a.

ANZ acquisitions⁽¹⁾

Transaction Overview							
Target	Date	Acquiror	Target Segment	Enterprise Value (A\$m)	EV/LTM Revenue	EV/NTM Revenue	EV/LTM EBITDA
 PowerHealth	Jul-24	 Health	Hospital admin (billing, budgeting)	n.a.	n.a.	n.a.	n.a.
	May-24	 Health	Pharmacy software	64.0	n.a.	n.a.	n.a.
 Health Businesses of Argus, Connecting Care & eReferrals	Jan-24		Messaging and eReferrals	n.a.	n.a.	n.a.	n.a.
	Dec-23		Breast Health	285.5	8.1x	n.a.	n.m
	Jul-23	 	Pharmacy software	6.3	1.1x	n.a.	3.4x
	Jun-23	 	Online medical clinic	133.0	n.a.	n.a.	n.a.
	Feb-23		Radiology sharing software	n.a.	n.a.	n.a.	n.a.
	Jul-22		Pharmacy software	7.6	1.3x	n.a.	n.a.
	Apr-22		Mobile diagnostics app	179.4	n.m	n.a.	n.m
	Jan-22	 	Payments	66.0	n.a.	n.a.	n.a.
	Jan-22		Telehealth	4.8	2.2x	n.a.	n.m
	Aug-21		Data analytics	19.6	1.8x	n.a.	7.4x
	Aug-21	 Health	EHR software	340.0	n.a.	n.a.	n.a.

ANZ acquisitions⁽¹⁾

Transaction Overview								
Target	Date	Acquiror	Target Segment	Enterprise Value (A\$m)	EV/LTM Revenue	EV/NTM Revenue	EV/LTM EBITDA	
 DR.INFO	Aug-21		Data analytics	n.a.	n.a.	n.a.	n.a.	
 PowerHealth	Jul-21		Hospital admin (billing, budgeting)	144.0	n.a.	n.a.	n.a.	
 Medipass	May-21		Payments	22.5	12.5x	n.a.	n.m	
	May-21		Booking and payments	42.5	n.a.	n.a.	n.a.	
	Apr-21		Aged and disability care software	17.9	n.a.	n.a.	n.a.	

Select ANZ private capital raisings⁽¹⁾

Transaction Overview		Details		
Company	Date	Segment	Investor(s)	Raising size (A\$m)
 splose	Feb-26	Practice management	 	46.0
 human.health	Oct-25	Prevention / Wellness	    	8.5
 Heidi	Oct-25	Clinical support	     	98.4
 Remedy Robotics	Oct-25	Treatment	    	12.0
 Lyrebird Health	Jun-25	Clinical support	  	12.0
 hola	Apr-25	Telehealth	 	6.0
 Sonder	Mar-25	Prevention / Wellness	   	40.0
 Heidi	Mar-25	Clinical support	      	26.5
 splose	Feb-25	Practice management		5.0
 VALD	Sep-24	Diagnostic		n.a.
 updoc	May-24	Telehealth		20.0
 Kismet	Mar-24	Care management	  	32.5
 carepatron	Nov-23	Practice management	 	6.0
 Heidi	Oct-23	Clinical support	      	10.0
 optain	May-23	Diagnostics / Imaging		12.0

Select ANZ private capital raisings⁽¹⁾

Transaction Overview		Details		
Company	Date	Segment	Investor(s)	Raising size (A\$m)
 eucalyptus	Apr-23	Telehealth	BLACKBIRD  Woolworths  BOND	50.0
 Toku	Apr-23	Diagnostics / Imaging	 national vision  TOPCON Healthcare	13.0
 mindset health	Mar-23	Treatment	 KING RIVER  Giant Leap  TEN MILE  Tattarang  Perennial Partners  Alberts	17.8
 InstantScripts	Mar-23	Telehealth; Pharmacy / Medication	BAILADOR	10.0
 Kismet	Feb-23	Care management	 airtree  black nova  FLYING FOX	4.0
 access telehealth	Dec-22	Telehealth	BAILADOR	12.5
 Sonder	Sep-22	Prevention and wellness	BLACKBIRD  seek  SecondQuarter  MA Growth Ventures	35.0
 HealthMatch	Sep-22	Clinical trials / research	 Square Peg  Folklore Ventures	10.0
 InstantScripts	Jul-22	Telehealth; Pharmacy / Medication	BAILADOR	5.0
 human.health	Jul-22	Prevention / Wellness	 airtree  SKIP CAPITAL	14.6
 eucalyptus	Jan-22	Telehealth	BLACKBIRD  ONE VENTURES  airtree  NVC  BOND  W23  ATHLETIC VENTURES	60.0
 Prospection.	Sep-21	Data / Analytics	 Horizons Ventures  Z  Ellerston Capital  MAIN SEQUENCE  CSIRO	45.0
 Heidi	Aug-21	Clinical support	BLACKBIRD  January Capital  A  possible VENTURES	5.0
 InstantScripts	Jul-21	Telehealth; Pharmacy / Medication	BAILADOR	5.5

Select ANZ private capital raisings⁽¹⁾

Transaction Overview		Details			
Company	Date	Segment	Investor(s)		Raising size (A\$m)
 eucalyptus	Jul-21	Telehealth	    	30.0	
 mindset health	Jun-21	Treatment	   	6.7	
 Sonder	Jun-21	Prevention / Wellness	 	16.0	



Public raisings

IPOs and secondaries



Trends in public raising activity

Commentary

- Secondary raising activity softened over the last 12 months (~\$561m across 18 deals vs \$986m across 25 in CY24) amid US FDA uncertainty and Australian sector headwinds following Opthea's Phase III failure
- The IPO window is showing early signs of life, with Tetratherix (Jun-25) trading ~30% above issue price. However results have been mixed, with Epiminder (Oct-25) dropping sharply post-listing and trading ~40% below issue, while smaller listings like Nexsen (Oct-25) have also struggled to gain traction.
- While a number of companies are queued for listings in 2026, mix-performances, limited specialist healthcare funds in Australia and a lack of natural lead investors continues to make domestic IPOs challenging
- As a result, companies are increasingly turning to strategic investments which offer better access to global capital pools. A weaker Australian dollar has also increased multinational appetite, with attractive entry valuations and lower cost of capital drawing offshore interest
- This trend has been evident in CY25 with secondaries led by US publicly listed corporates providing technology validation. Keysight Technologies (NYSE:KEYS), a US\$30bn+ electronic test & measurement company, backed EMVision's portable brain imaging technology across two rounds (\$15m Feb-24, \$12m Sep-25). Similarly, Lantheus Holdings (NASDAQ:LNTH), a ~US\$5bn radiopharmaceutical specialist, has continued to support RAD's theranostics platform (\$70m Jun-24, \$35m Oct-25)


2026 Outlook

- ASX Healthcare is trading at multi-year lows while global healthcare PE deployment reached record levels – positions Australia for renewed international capital inflows in 2026. Further IPO activity is expected as the window stabilises, alongside continued interest from US and offshore corporates seeking technology validation and strategic optionality. Companies that can demonstrate de-risked assets, clear path to scale, and differentiated IP will be best positioned to attract capital.

Select secondary raise transactions

Date	Company	Raising size (\$Am)	Market cap. at issue (\$Am)	Premium (Discount) to last close ⁽¹⁾	Premium (Discount) to VWAP ⁽²⁾
Oct-25	 RAD ⁽²⁾ <small>RADIO PHARM THERANOSTICS</small>	35.0	68.6	(18.9%)	(16.7%)
Sep-25	 ARTRYA	75.0	250.6	(6.0%)	(4.7%)
Feb-25	 PYC Therapeutics	145.8	669.1	(2.7%)	(4.9%)
Jun-24	 RAD ⁽²⁾ <small>RADIO PHARM THERANOSTICS</small>	70.0	18.4	(17.6%)	(23.1%)
Jun-24	 botanix PHARMACEUTICALS	70.0	624.5	(10.4%)	2.8%
Jun-24	 immutep LAG-3 IMMUNOTHERAPY	100.2	562.7	(15.6%)	(14.0%)
Median				(13.0%)	(4.8%)

Secondary raises volume / value⁽¹⁾



Recent and upcoming ASX MedTech IPO activity

The IPO window for MedTech is reopening with 3 health/life science listings in CY25, and other IPOs pending.

Company	Ticker	Listing date	Overview / insights	Raising size	Valuation
 I-MED Network Radiology	TBC	CY2026	<ul style="list-style-type: none"> Medical imaging company that provides diagnostic imaging services, including X-rays, CT scans, MRI scans, and ultrasound Operate a large network of radiology clinics 	~\$1bn ⁽¹⁾	~\$3bn ⁽¹⁾
 Tetratherix™	ASX:TTX	30 June 2025	<ul style="list-style-type: none"> Regenerative medicine platform for bone regeneration, tissue spacing, tissue healing Share price traded positively since listing up ~18% on offer price 	\$25m	\$145m / \$2.88p.s.
 Nexsen	ASX:NXN	14 October 2025	<ul style="list-style-type: none"> Point-of-care diagnostics using nanoparticle/aptamer platform; lead product StrepSure® for Group B Streptococcus detection in pregnancy Despite increasing by ~40% post listing, now trading back at offer price of \$0.20 p.s. 	\$6-8m (\$0.20 p.s)	\$32m / \$0.20p.s.
 epiminder	ASX:EPI	1 December 2025	<ul style="list-style-type: none"> Scalp implant device which monitors the brain's electrical activity to detect and track epileptic seizures 	\$125m (\$1.50 p.s)	\$325m / \$1.50p.s.
 saluda MEDICAL	ASX:SLD	5 December 2025	<ul style="list-style-type: none"> Medical device which is used to treat conditions such as chronic pain or movement disorders 	\$230m	\$775m / \$2.65p.s.
 QBiotics Group	TBC	CY2026	<ul style="list-style-type: none"> Develops novel, plant-derived small molecules for treating oncology and wound healing 	n/a	n/a
 HaemaLogiX	TBC	CY2026	<ul style="list-style-type: none"> Blood cancer immunotherapies (CAR-T, monoclonal antibodies) Former Health Minister Greg Hunt on board and former Macquarie CEO Allan Moss invested Partnership with Peter MacCallum Cancer Centre; first patient treatments commencing 	~\$50m ⁽²⁾	TBC

Precedent public raisings activity (1/4)

Overview			Details				
Company	Ticker	Raising date	Use of proceeds	Market cap. at issue (\$Am)	Raising size ⁽¹⁾ (\$Am)	Premium (Discount) to last close ⁽²⁾	Premium (Discount) to VWAP ⁽³⁾
	ASX:AVR	Oct-25	General Corporate Purposes, Product Development/R&D, Working Capital	274.0	20.9	(14.8%)	11.3%
	ASX:OCC	Oct-25	Working Capital	283.3	30.0	(9.1%)	22.8%
	ASX:RAD	Oct-25	Product Development/R&D, Working Capital	68.6	35.0	(18.9%)	(16.7%)
	ASX:EMV	Sep-25	General Corporate Purposes, Product Development/R&D, Working Capital	175.3	12.0	(16.4%)	(6.6%)
	ASX:AYA	Sep-25	Product Development/R&D, Working Capital	250.6	75.0	(6.0%)	(4.7%)
	ASX:ATH	Sep-25	General Corporate Purposes, Working Capital, Development Capital	119.7	20.0	(7.7%)	(7.3%)
	ASX:OIL	Aug-25	Working Capital	71.0	17.8	13.3%	n.a.
	ASX:ATX	Jul-25	Product Development/R&D, Working Capital	84.7	25.0	(19.3%)	(22.8%)
	ASX:IMU	Jul-25	Product Development/R&D, Working Capital	83.5	22.5	(22.4%)	(19.6%)
	ASX:VHL	Jul-25	Working Capital	50.5	11.0	(23.1%)	(16.2%)
	ASX:MAP	Jun-25	Product Development/R&D, Working Capital	51.8	12.5	(21.7%)	(25.9%)
	ASX:BOT	Apr-25	Working Capital	820.7	40.0	(7.0%)	(13.8%)

Source: Capital IQ, company filings, Blackpeak Capital, Australian Financial Review
 (1) Excludes raisings sizes of less than \$10m.
 (2) Calculated from the close off the undisturbed share price.
 (3) Per company announcements where reported. Period of reported VWAPs vary.

Precedent public raisings activity (2/4)

Overview			Details				
Company	Ticker	Raising date	Use of proceeds	Market cap. at issue (\$Am)	Raising size ⁽¹⁾ (\$Am)	Premium (Discount) to last close ⁽²⁾	Premium (Discount) to VWAP ⁽³⁾
 Recce Pharmaceuticals	ASX:RCE	Apr-25	Product Development/R&D, Working Capital	85.2	10.8	(13.8%)	(19.8%)
 aróvella THERAPEUTICS	ASX:ALA	Feb-25	Product Development/R&D, Working Capital	143.7	15.0	(35.9%)	(33.1%)
 4DMedical™	ASX:4DX	Feb-25	Working Capital	158.0	12.5	(22.7%)	(2.5%)
 PYC Therapeutics	ASX:PYC	Feb-25	Product Development/R&D, Working Capital	669.1	145.8	(2.7%)	(4.9%)
ARTRYA	ASX:AYA	Feb-25	Product Development/R&D, Working Capital	75.0	15.0	(15.1%)	(10.4%)
 Alterity THERAPEUTICS	ASX:ATH	Feb-25	Product Development/R&D, Working Capital	108.8	40.0	(8.3%)	10.2%
 SYNTARA	ASX:SNT	Dec-24	Product Development/R&D, Working Capital	87.9	15.0	(10.4%)	(10.6%)
 LTR Pharma	ASX:LTP	Dec-24	Product Development/R&D, Working Capital	150.7	25.0	(12.4%)	(21.6%)
 PARADIGM BIOPHARMA	ASX:PAR	Dec-24	Product Development/R&D, Working Capital	186.9	16.0	(31.0%)	(15.5%)
 ortho-cell	ASX:OCC	Oct-24	Working Capital	148.3	17.0	(13.0%)	(4.1%)
 percheron THERAPEUTICS	ASX:PER	Oct-24	Product Development/R&D, Working Capital	73.9	13.0	(11.1%)	(25.3%)
 Medical Developments International	ASX:MVP	Jul-24	Working Capital	47.0	10.0	(21.6%)	(21.0%)

Source: Capital IQ, company filings, Blackpeak Capital, Australian Financial Review
 (1) Excludes raisings sizes of less than \$10m.
 (2) Calculated from the close off the undisturbed share price.
 (3) Per company announcements where reported. Period of reported VWAPs vary.

Precedent public raisings activity (3/4)

Overview			Details				
Company	Ticker	Raising date	Use of proceeds	Market cap. at issue (\$Am)	Raising size ⁽¹⁾ (\$Am)	Premium (Discount) to last close ⁽²⁾	Premium (Discount) to VWAP ⁽³⁾
	ASX:LTP	Jul-24	Working Capital	112.9	10.5	(18.9%)	(16.0%)
	ASX:AVR	Jul-24	Product Development/R&D, Working Capital	301.8	30.0	(6.2%)	0.0%
	ASX:RAD	Jun-24	Product Development/R&D, Working Capital	18.4	70.0	(17.6%)	(23.1%)
	ASX:BDX	Jun-24	Product Development/R&D, Working Capital	46.4	10.5	(28.6%)	(21.7%)
	ASX:GSS	Jun-24	Product Development/R&D, Working Capital	163.6	30.0	2.7%	0.1%
	ASX:NUZ	Jun-24	Working Capital	95.9	10.0	(15.6%)	(19.8%)
OPTHEA	ASX:OPT	Jun-24	General Corporate Purposes, Working Capital, Development Capital	414.8	227.4	(17.5%)	2.4%
	ASX:BOT	Jun-24	Working Capital	624.5	70.0	(10.4%)	2.8%
	ASX:IMM	Jun-24	Working Capital	562.7	100.2	(15.6%)	(14.0%)
	ASX:CYC	May-24	Product Development/R&D, Working Capital	130.9	20.0	(13.9%)	1.1%
	ASX:SOM	Apr-24	General Corporate Purposes, Working Capital, Exploration	29.3	22.6	(45.5%)	(4.7%)
	ASX:AGN	Apr-24	Product Development/R&D	56.9	12.0	(18.1%)	(19.4%)

Source: Capital IQ, company filings, Blackpeak Capital, Australian Financial Review
 (1) Excludes raisings sizes of less than \$10m.
 (2) Calculated from the close off the undisturbed share price.
 (3) Per company announcements where reported. Period of reported VWAPs vary.

Precedent public raisings activity (4/4)

Overview			Details				
Company	Ticker	Raising date	Use of proceeds	Market cap. at issue (\$Am)	Raising size ⁽¹⁾ (\$Am)	Premium (Discount) to last close ⁽²⁾	Premium (Discount) to VWAP ⁽³⁾
 Neurotech International	ASX:NTI	Apr-24	Product Development/R&D, Working Capital	91.7	10.0	(4.8%)	(4.7%)
 ANTERIS TECHNOLOGIES	ASX:AVR	Apr-24	Product Development/R&D, Working Capital	444.0	23.0	0.0%	(0.9%)
 aróvella THERAPEUTICS	ASX:ALA	Mar-24	Working Capital	120.3	12.5	(23.1%)	(19.7%)
 Dimerix	ASX:DXB	Mar-24	Working Capital	144.8	20.0	0.0%	14.5%
 PYC Therapeutics	ASX:PYC	Mar-24	Product Development/R&D, Working Capital	452.6	74.6	(5.9%)	(1.2%)
 CLARITY PHARMACEUTICALS	ASX:CU6	Mar-24	Working Capital	733.8	121.0	(10.5%)	(12.5%)
 EMVISION	ASX:EMV	Feb-24	Working Capital	226.4	15.3	(4.2%)	0.0%
Median						(13.9%)	(10.6%)

Source: Capital IQ, company filings, Blackpeak Capital, Australian Financial Review

(1) Excludes raisings sizes of less than \$10m.

(2) Calculated from the close off the undisturbed share price.


(3) Per company announcements where reported. Period of reported VWAPs vary.

Blackpeak's approach to investor outreach

Our approach is to educate and identify the right partners to support your current and future capital requirements.

Philosophy to identify the appropriate long-term investment partners – not necessarily “deal active investors”.

We have good engagement with the majority of the domestic and APAC institutions / family offices and angel investors, including recent engagement with specialist health-tech and life science funds in **the middle east, Europe, the United Kingdom, United States and Canada.**



Considerations for listed companies when targeting investors

Each target investor group differs in technical knowledge, industry dynamics, the broader market opportunity and business model which Blackpeak and management would consider prior to advancing discussions:

	Strategics	Healthcare funds	Generalist funds
Involvement	<ul style="list-style-type: none"> Active involvement in operational, strategic and technical direction Requires clear alignment between company and the strategic prior to investment on long-term strategy Trade-off between including strategic that can add value beyond capital vs giving up longer term optionality 	<ul style="list-style-type: none"> Aligned focused on achieving strategic goals to maximise the broader market opportunity Company retains control over product and technical direction Require engagement and communication on progress achieving operational and technical milestones 	<ul style="list-style-type: none"> Passive investor with limited involvement Company retains control over long-term product and market strategy Require engagement and communication on progress achieving operational and technical milestones
Knowledge	<ul style="list-style-type: none"> Greater understanding of product roadmap and proprietary technology than generalists Less time required to educate on industry and competitive dynamics More challenging to reposition company story given prior knowledge and understanding of business 	<ul style="list-style-type: none"> Given limited company knowledge there is an opportunity to position favourable growth story Moderate level of time and resource to educate on commercial drivers and competitive advantage relative to peers 	<ul style="list-style-type: none"> Limited to no knowledge of company and story to date Significant education required to understand the industry, market opportunity and business model – prior to any technical discussions Typically draw on comparisons to relevant peers
Market	<ul style="list-style-type: none"> Validation from the market given the strategics knowledge of technical capabilities, competitive landscape, industry and ability to support further growth 	<ul style="list-style-type: none"> Through the validation of a specialised healthcare fund, company is positioned strongly relative to peers 	<ul style="list-style-type: none"> Provides visible institutional support and confidence to the market on achieving operational and commercial milestones
Focus areas	<ul style="list-style-type: none"> High focus on understanding technical nuances of core product and platform potential, existing agreements and the positioning of company in the market 	<ul style="list-style-type: none"> High focus on positioning in the market and broader opportunity Moderate focus on understanding technical nuances Understanding the industry landscape and ensuring a competitive advantage over its peers 	<ul style="list-style-type: none"> Timing of key technical and operational milestones (potential key catalyst) More focused on broad understanding of the platform potential rather than specific technical capabilities Engagement from either strategic or healthcare funds to assist in validating their investment



Comparable trading detail

Domestic healthcare software, diagnostics and MedTech



Listed healthcare software trading performance

Company	Share price data					Trading multiples						Operating metrics								
	Trading data			Capitalisation (A\$m)		EV / Revenue			EV / EBITDA			Revenue Growth			Gross margin			EBITDA margin		
	Share price	% of 52-week high/ low	3-month perf.	Market cap.	Ent. value	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E
ANZ Healthcare Software																				
Pro Medicus	184.12	55% / 114%	2%	19,235	19,027	89.3x	66.9x	51.4x	n.a.	n.a.	n.a.	32%	34%	30%	100%	100%	100%	75%	79%	81%
4DMedical	3.17	58% / 1409%	82%	1,806	1,804	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	56%	43%	264%	92%	93%	82%	(425%)	(362%)	(51%)
Artrya Limited	3.53	67% / 630%	4%	558	547	n.a.	54.7x	32.2x	n.a.	n.a.	n.a.	n.a.	n.a.	70%	n.a.	n.a.	n.a.	n.a.	(150%)	(53%)
Alcidion	0.12	79% / 189%	24%	154	138	3.4x	2.7x	2.6x	27.1x	12.1x	13.6x	10%	27%	4%	38%	88%	88%	12%	22%	19%
Mach7	0.42	61% / 148%	38%	98	80	2.4x	2.3x	2.0x	n.a.	n.a.	30.7x	16%	2%	15%	94%	n.a.	n.a.	(1%)	2%	7%
BlinkLab Limited	0.93	84% / 300%	42%	117	110	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Optiscan	0.10	58% / 122%	(20%)	100	97	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	(18%)	n.a.	n.a.	81%	n.a.	n.a.	n.a.	n.a.	n.a.
Singular Health Group Ltd	0.25	58% / 136%	(14%)	77	64	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
ImpediMed	0.02	39% / 128%	(39%)	47	39	3.1x	2.2x	1.5x	n.a.	n.a.	n.a.	23%	40%	46%	42%	86%	87%	n.a.	(71%)	(27%)
Beamtree	0.20	61% / 118%	(9%)	58	57	2.0x	1.8x	1.4x	n.a.	n.a.	18.2x	4%	10%	25%	17%	n.a.	n.a.	(2%)	3%	8%
PainChek	0.26	24% / 113%	(47%)	53	47	14.0x	n.a.	n.a.	n.a.	n.a.	n.a.	26%	n.a.	n.a.	32%	n.a.	n.a.	n.a.	n.a.	n.a.
Median⁽¹⁾						3.1x	2.3x	2.0x	27.1x	12.1x	18.2x	16%	27%	36%	42%	88%	87%	(1%)	(34%)	(10%)
Average⁽¹⁾						5.0x	12.7x	7.9x	27.1x	12.1x	20.8x	17%	24%	71%	56%	89%	86%	(104%)	(93%)	(16%)
Max⁽¹⁾						14.0x	54.7x	32.2x	27.1x	12.1x	30.7x	56%	43%	264%	94%	93%	88%	12%	22%	19%
Min⁽¹⁾						2.0x	1.8x	1.4x	27.1x	12.1x	13.6x	(18%)	2%	4%	17%	86%	82%	(425%)	(362%)	(53%)

Note: Market data as at 31 January 2026. Excludes constituents with <\$30m market capitalisation. Net debt includes 'debt like items' such as lease liabilities

Source: Blackpeak Capital, Capital IQ, ASX company filings.

(1) Pro Medicus excluded from calculations due to multiples being deemed as outliers.

Listed medical devices trading performance

Company	Share price data					Trading multiples						Operating metrics								
	Trading data			Capitalisation (A\$m)		EV / Revenue			EV / EBITDA			Revenue Growth			Gross margin			EBITDA margin		
	Share price	% of 52-week high/ low	3-month perf.	Market cap.	Ent. value	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E	FY25A	FY26E	FY27E
Vertical																				
ANZ Medical Devices																				
ResMed	258.31	88% / 129%	98%	54,191	53,422	7.3x	6.6x	6.2x	20.1x	17.0x	15.8x	10%	10%	7%	100%	62%	63%	36%	39%	39%
Nanosonics	3.88	75% / 119%	(15%)	1,177	1,023	5.2x	4.7x	4.3x	39.5x	38.7x	27.7x	17%	10%	10%	78%	76%	77%	13%	12%	15%
PolyNovo	1.02	49% / 109%	(23%)	701	685	5.4x	4.4x	3.5x	n.a.	34.8x	18.2x	23%	24%	23%	84%	93%	92%	9%	13%	20%
Cogstate	1.50	72% / 187%	71%	369	319	4.2x	3.5x	3.1x	13.9x	11.8x	9.6x	22%	20%	13%	57%	n.a.	n.a.	30%	29%	32%
Aroa Biosurgery	0.72	78% / 179%	(19%)	216	201	2.6x	2.3x	2.0x	n.a.	25.5x	13.3x	23%	15%	18%	87%	85%	85%	5%	7%	14%
Lumos Diagnostics	0.15	65% / 1132%	5%	170	178	10.0x	5.5x	4.5x	n.a.	n.a.	n.a.	11%	83%	22%	67%	51%	64%	(28%)	12%	10%
tetratherix	3.99	71% / 139%	(7%)	203	175	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	22%	47%	37%	100%	n.a.	n.a.	n.a.	n.a.	n.a.
CleanSpace	0.66	75% / 178%	(6%)	52	46	2.3x	2.0x	1.7x	n.a.	38.2x	13.9x	26%	17%	20%	74%	75%	74%	(2%)	5%	12%
Next Science	0.10	94% / 259%	(3%)	42	49	3.0x	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	38%	n.a.	n.a.	n.a.	n.a.	n.a.
Genetic Signatures	0.16	22% / 115%	(49%)	35	29	1.8x	1.5x	1.0x	n.a.	n.a.	n.a.	62%	19%	45%	53%	57%	65%	(99%)	(82%)	(37%)
CONNEQT	0.05	29% / 173%	32%	28	29	8.1x	n.a.	n.a.	n.a.	n.a.	n.a.	(67%)	n.a.	n.a.	93%	n.a.	n.a.	n.a.	n.a.	n.a.
Atomo Diagnostics	0.04	79% / 271%	41%	31	28	7.3x	n.a.	n.a.	n.a.	n.a.	n.a.	(7%)	n.a.	n.a.	44%	n.a.	n.a.	n.a.	n.a.	n.a.
Adherium	0.01	46% / 200%	33%	19	22	26.5x	n.a.	n.a.	n.a.	n.a.	n.a.	(3%)	n.a.	n.a.	32%	n.a.	n.a.	n.a.	n.a.	n.a.
Median						5.3x	3.9x	3.3x	20.1x	30.1x	14.8x	19%	19%	20%	74%	75%	74%	7%	12%	15%
Average						7.0x	3.8x	3.3x	24.5x	27.7x	16.4x	13%	27%	22%	73%	71%	74%	(4%)	4%	13%
Max						26.5x	6.6x	6.2x	39.5x	38.7x	27.7x	62%	83%	45%	100%	93%	92%	36%	39%	39%
Min						1.8x	1.5x	1.0x	13.9x	11.8x	9.6x	(67%)	10%	7%	38%	51%	63%	(99%)	(82%)	(37%)



📍 Level 3, 6 O'Connell St Sydney NSW 2000

☎ +61 2 8823 3464

✉ inquiries@blackpeakcapital.com.au

🌐 www.blackpeakcapital.com.au